ElMindA has entered into a strategic, multi-year research collaboration agreement with Purdue Pharma L.P., a leading developer of pharmacologic therapies to treat and manage pain. The staged research collaboration will focus on pain diagnosis and management, through the development of objective assessments of analgesia as well as other subjective responses to treatment, and include several projects aimed at the discovery and development of new clinical diagnostic tests and biomarkers to manage pain and to enable the development of more effective pain treatments. ElMindA’s BNA™ technology combines advanced brain imaging tools with ElMindA’s proprietary algorithms and signal processing to produce brain functional mapping. In the area of drug development, the BNA™ technology can shed light on the dynamic functional changes in brain networks pre- and post-drug administration to reveal mechanisms of action, optimize drug dosages and identify responders and non-responders to therapies early in the drug development process. Clinical diagnostic tests to improve pain management and biomarkers for drug development resulting from the collaboration will be used and commercialized by ElMindA and/or Purdue. ElMindA was founded in 2006 with the vision of revolutionizing the management of brain disorders and injuries by transforming state-of-the-art neuroscience into bed-side clinical practice, opening a new window into functionality of the brain. The company seeks to dramatically improve clinical decision-making for Central Nervous System (CNS) disease management through wide utilization of its BNA™ testing as an objective measurement of brain function, dysfunction, disease progression and recovery. The ElMindA BNA™ technology is currently being used for drug development research with leading pharmaceutical companies and in research with prominent academic research centers throughout the U.S. and Europe. In 2012,ElMindA submitted the technology for FDA clearance. The technology is not currently cleared for clinical use.